Z Squared Inc. quarterly report, Q1 FY2025

SEC Filing Summary: Coeptis Therapeutics Holdings, Inc. (COEP)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company operating through two segments: Biotechnology (cell therapy platforms for cancer and autoimmune diseases) and Technology (AI-powered marketing and automation). The company is classified as a smaller reporting company and an emerging growth company. As of May 14, 2025, there were 3,513,838 shares of common stock outstanding.

Key Financial Metrics

Metric Q1 2025 Q1 2024
Revenue $62,874 $0
Net Loss $(3,420,941) $(3,001,388)
Loss Per Share (Basic & Diluted) $(1.11) $(0.08)
Cash and Cash Equivalents $4,268,368 $1,029,244
Total Assets $13,453,067 $8,908,660
Total Liabilities $5,990,153 $5,041,434
Convertible Notes Payable (Net) $1,739,244 $1,087,873
Notes Payable (In Default) $100,000 $100,000
Operating Cash Flow $(2,366,167) $(1,902,390)
Financing Cash Flow $6,101,650 $1,562,500

Material Changes vs. Prior Period

  • Liquidity Improvement: Cash balances increased significantly from $1.03 million to $4.27 million, driven primarily by a $5.33 million Series A preferred stock offering and $990,000 in proceeds from notes payable.
  • Revenue Recognition: The company recorded $62,874 in revenue from technology services (advertising campaigns and webinars), compared to zero in the prior year. A customer deposit of $1.19 million was recorded as a liability.
  • Expense Fluctuations: Total operating expenses rose to $4.07 million from $2.92 million. This increase was driven by higher professional services ($2.33M vs $1.18M) and stock-based compensation ($598K vs $97K). Conversely, R&D expenses decreased significantly to $87K from $777K due to the termination of a Shared Services Agreement with Deverra Therapeutics.
  • Derivative Gains: The company recognized a $596,120 gain from the change in fair value of derivative liabilities, compared to a $34,875 gain in the prior year, largely due to changes in stock price and volatility assumptions.
  • Debt Status: A $100,000 note payable remains in default. However, a $218,750 convertible note to Purple Biotech was paid in full during the quarter.

Outlook, Risks, and Unusual Items

  • Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern due to an accumulated deficit of $101.7 million and recurring net losses. Continued operations depend on raising additional capital.
  • Strategic Transactions:
    • Merger Agreement: On April 25, 2025, the company entered into a merger agreement to acquire Z Squared, Inc., with a plan to spin out its biotechnology operations to existing shareholders prior to closing.
    • SEPA: A Standby Equity Purchase Agreement with Yorkville allows the company to sell up to $20 million of common stock. A related convertible note of $1.3 million was issued.
  • Capital Structure: The company completed a $10 million Series A preferred stock offering in February 2025. 6,200 shares of Series A preferred stock were converted to common stock during the quarter.
  • Internal Controls: Management concluded that disclosure controls and procedures were effective as of March 31, 2025, following remediation of material weaknesses identified in 2023.

Investor Verification Checklist

  • Default Status: Verify the status of the $100,000 note payable listed as "in default" and potential acceleration risks.
  • Merger Terms: Review the specific terms of the April 25, 2025 merger with Z Squared, Inc., particularly the "Spin Out" of biotechnology assets and the exchange ratio for shareholders.
  • Derivative Valuation: Assess the sensitivity of the $635,489 derivative liability to stock price volatility, as changes significantly impact net income.
  • Revenue Sustainability: Evaluate the concentration risk of revenue, which currently relies on two customers accounting for 100% of sales.
  • Cash Burn Rate: Monitor the burn rate against the $4.27 million cash balance to determine the runway before further dilution or debt financing is required.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.